Entero Therapeutics (Nasdaq:ENTO) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ENTO Aperçu des actions

ENTO analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	0/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus ont augmenté 2.3% par an au cours des 5 dernières années

Analyse des risques

Réalise moins d'un million de dollars de revenus ( $0 )

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

N'a pas de capitalisation boursière significative ( $968K )

Cours de l'action très volatil au cours des 3 derniers mois

+ 1 plus de risques

Entero Therapeutics, Inc. Concurrents

Quoin Pharmaceuticals

NasdaqCM:QNRX

US$1.9m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.0m

Dermata Therapeutics

NasdaqCM:DRMA

US$1.9m

Cyclacel Pharmaceuticals

NasdaqCM:CYCC

US$1.8m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Entero Therapeutics
Historique des cours de bourse
Prix actuel de l'action	US$0.60
Plus haut sur 52 semaines	US$14.51
Plus bas sur 52 semaines	US$0.18
Bêta	1.37
1Variation sur 1 mois	51.82%
Variation sur 3 mois	-42.34%
Variation sur 1 an	-90.91%
3Variation sur 3 ans	-99.99%
Variation sur 5 ans	-100.00%
Évolution depuis l'introduction en bourse	-100.00%

Nouvelles et mises à jour récentes

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Rendement pour les actionnaires

	ENTO	US Biotechs	US Marché
7D	74.5%	-0.5%	0.4%
1Y	-90.9%	18.3%	32.6%

Rendement vs Industrie: ENTO a sous-performé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: ENTO a sous-performé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	32.1%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de ENTO a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ENTO est passée de 23% à 32% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2014	9	James Sapirstein	www.enterothera.com

Entero Therapeutics, Inc. est une société biopharmaceutique en phase clinique qui se consacre au développement de thérapies ciblées et administrées par voie orale pour le traitement des patients souffrant de maladies gastro-intestinales. Les produits candidats de la société comprennent la latigluténase, un produit biothérapeutique oral ciblé pour la maladie cœliaque, conçu pour décomposer le gluten en peptides non immunogènes, qui fait actuellement l'objet d'études de phase 2, et le capeserod, un agoniste partiel sélectif du récepteur 5-HT4 qui fait l'objet d'études de phase 1 pour le traitement de la gastroparésie. Elle participe également au développement de l'adrulipase, une enzyme lipase recombinante conçue pour permettre la digestion des graisses et d'autres nutriments, qui fait actuellement l'objet d'études de phase 2 pour le traitement de l'insuffisance pancréatique exocrine chez les patients atteints de mucoviscidose et de pancréatite chronique ; et le niclosamide, une petite molécule orale avec inhibiteur anti-inflammatoire, actuellement en phase 2 d'études pour le traitement de la proctite ulcéreuse et de la proctosigmoïdite ulcéreuse, ainsi que de la colite et de la diarrhée associées aux inhibiteurs du point de contrôle immunitaire chez les patients atteints d'un cancer métastatique.

Entero Therapeutics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Entero Therapeutics se comparent-ils à sa capitalisation boursière ?
ENTO statistiques fondamentales
Capitalisation boursière	US$1.95m
Bénéfices(TTM)	-US$6.44m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-0.3x

Ratio P/E

Le site ENTO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ENTO compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	US$6.44m
Les revenus	-US$6.44m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.98
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	8.7%

Quelles ont été les performances à long terme de ENTO?

Voir les performances historiques et les comparaisons

ENTO Aperçu des actions

Récompenses

Analyse des risques

Entero Therapeutics, Inc. Concurrents

NasdaqCM:QNRX

US$1.9m

NasdaqCM:SLRX

US$2.0m

NasdaqCM:DRMA

US$1.9m

NasdaqCM:CYCC

US$1.8m

Historique des prix et performances

Nouvelles et mises à jour récentes

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

Recent updates

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency